The role and efficacy of Teclistamab

Teritusumab injection is indicated for the treatment of relapsed or refractory multiple myeloma (cancer that has not responded to treatment) in patients who have received at least 4 prior lines of therapy. These prior treatments included proteasome inhibitors, immunomodulators, and antiCD38monoclonal antibodies. Teritusumab is a bispecific T cell-binding antibody that binds to TCD3 receptors and polypeptides expressed on the surface of T cells. Myeloma cells bind to B cell maturation antigen (BCMA) expressed on the surface of some healthy B cells. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.